![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Narayana Nethralaya |
---|---|
Information provided by: | Narayana Nethralaya |
ClinicalTrials.gov Identifier: | NCT00403026 |
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.
Condition | Intervention |
---|---|
Wet AMD Macular Oedema Proliferative Diabetic Retinopathy |
Drug: Bevacizumab ( Avastin) |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Off-Label,Intravitreal Use of Bevacizumab for Retinal Disorders |
Estimated Enrollment: | 150 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | November 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: sivakami pai, MS | 91-80-23373311 ext 27 | shivsudhir@gmail.com |
Contact: shubha anil | 91-80-23373311 ext 33 | info@narayananethralaya.com |
India | |
Sivakami Pai | Recruiting |
BANGALORE, India, 560010 | |
Contact: sivakami pai, MS 91-80-23373311 ext 27 shivsudhir@gmail.com | |
Principal Investigator: SIVAKAMI PAI, MS |
Principal Investigator: | sivakami pai, MS | Narayana Nethralaya, Bangalroe, India |
Study ID Numbers: | NN-002/2006 |
Study First Received: | November 22, 2006 |
Last Updated: | November 22, 2006 |
ClinicalTrials.gov Identifier: | NCT00403026 |
Health Authority: | India: Institutional Review Board |
Bevacizumab (Avastin) Intravitreal injection VEGF CRVO |
BRVO PDR CNVM |
Eye Diseases Vascular Diseases Diabetes Mellitus Edema Endocrine System Diseases Macular Degeneration Retinal Degeneration Bevacizumab |
Diabetic Angiopathies Macular Edema Diabetic Retinopathy Endocrinopathy Retinal Diseases Diabetes Complications Retinal degeneration |
Antineoplastic Agents Therapeutic Uses Growth Substances Physiological Effects of Drugs Cardiovascular Diseases |
Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions |